Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Junqi Niu

Showing results (231-240 of 280) with videos related to

Pageof 28
Sort By:
Gut|June 20, 2024
High accuracy model for HBsAg loss based on longitudinal trajectories of serum qHBsAg throughout long-term antiviral therapyRong Fan, Siru Zhao, Junqi Niu, et al.
Hepatology International|May 23, 2026
Safety, pharmacokinetics and antiviral activity of AHB‑137 in healthy volunteers and chronic hepatitis B patients: a phase 1a/1b studyWen Wang, Jiajia Mai, Jinlin Hou, et al.
Cellular & Molecular Immunology|April 3, 2020
Junctional and somatic hypermutation-induced CX<sub>4</sub>C motif is critical for the recognition of a highly conserved epitope on HCV E2 by a human broadly neutralizing antibodyChunyan Yi, Jing Xia, Lan He, et al.
Gut|January 15, 2015
Baseline quantitative hepatitis B core antibody titre alone strongly predicts HBeAg seroconversion across chronic hepatitis B patients treated with peginterferon or nucleos(t)ide analoguesRong Fan, Jian Sun, Quan Yuan, et al.
BMC Public Health|September 5, 2018
Epidemiological study of hepatitis B and hepatitis C infections in Northeastern China and the beneficial effect of the vaccination strategy for hepatitis B: a cross-sectional studyShishen Wang, Yuhui Tao, Yuchun Tao, et al.
Scientific Reports|November 29, 2016
Female gender lost protective effect against disease progression in elderly patients with chronic hepatitis BHong You, Yuanyuan Kong, Jinlin Hou, et al.
Journal of Hepatology|June 18, 2026
Interleukin-19 ameliorates drug-induced liver injury by limiting proinflammatory macrophage infiltration via SUMOylation of C/EBPβPeng Xiao, Qiuhong Zai, Ningning Ma, et al.
Hepatology (Baltimore, Md.)|December 15, 2007
Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trialJinlin Hou, You-Kuan Yin, Daozhen Xu, et al.
Journal of Viral Hepatitis|January 26, 2022
Efficacy and safety of alfosbuvir plus daclatasvir in Chinese patients with hepatitis C virus genotypes 1, 2, 3, and 6 infection: An open-label, phase 2 studyRui Hua, Fei Kong, Xiaofeng Wen, et al.
Journal of Gastroenterology and Hepatology|March 23, 2016
A phase 3, open-label study of daclatasvir plus asunaprevir in Asian patients with chronic hepatitis C virus genotype 1b infection who are ineligible for or intolerant to interferon alfa therapies with or without ribavirinLai Wei, Mingxiang Zhang, Min Xu, et al.
Pageof 28

Showing results (231-240 of 280) with videos related to

Sort By:
Pageof 28
Gut|June 20, 2024
High accuracy model for HBsAg loss based on longitudinal trajectories of serum qHBsAg throughout long-term antiviral therapyRong Fan, Siru Zhao, Junqi Niu, et al.
Hepatology International|May 23, 2026
Safety, pharmacokinetics and antiviral activity of AHB‑137 in healthy volunteers and chronic hepatitis B patients: a phase 1a/1b studyWen Wang, Jiajia Mai, Jinlin Hou, et al.
Cellular & Molecular Immunology|April 3, 2020
Junctional and somatic hypermutation-induced CX<sub>4</sub>C motif is critical for the recognition of a highly conserved epitope on HCV E2 by a human broadly neutralizing antibodyChunyan Yi, Jing Xia, Lan He, et al.
Gut|January 15, 2015
Baseline quantitative hepatitis B core antibody titre alone strongly predicts HBeAg seroconversion across chronic hepatitis B patients treated with peginterferon or nucleos(t)ide analoguesRong Fan, Jian Sun, Quan Yuan, et al.
BMC Public Health|September 5, 2018
Epidemiological study of hepatitis B and hepatitis C infections in Northeastern China and the beneficial effect of the vaccination strategy for hepatitis B: a cross-sectional studyShishen Wang, Yuhui Tao, Yuchun Tao, et al.
Scientific Reports|November 29, 2016
Female gender lost protective effect against disease progression in elderly patients with chronic hepatitis BHong You, Yuanyuan Kong, Jinlin Hou, et al.
Journal of Hepatology|June 18, 2026
Interleukin-19 ameliorates drug-induced liver injury by limiting proinflammatory macrophage infiltration via SUMOylation of C/EBPβPeng Xiao, Qiuhong Zai, Ningning Ma, et al.
Hepatology (Baltimore, Md.)|December 15, 2007
Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trialJinlin Hou, You-Kuan Yin, Daozhen Xu, et al.
Journal of Viral Hepatitis|January 26, 2022
Efficacy and safety of alfosbuvir plus daclatasvir in Chinese patients with hepatitis C virus genotypes 1, 2, 3, and 6 infection: An open-label, phase 2 studyRui Hua, Fei Kong, Xiaofeng Wen, et al.
Journal of Gastroenterology and Hepatology|March 23, 2016
A phase 3, open-label study of daclatasvir plus asunaprevir in Asian patients with chronic hepatitis C virus genotype 1b infection who are ineligible for or intolerant to interferon alfa therapies with or without ribavirinLai Wei, Mingxiang Zhang, Min Xu, et al.
Pageof 28